Birdwatch Note
2024-10-15 09:02:58 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
本治験は A群:ワクチン→3か月程観察①A→プラセボ→4か月程観察②A B群:プラセボ→3か月間観察①B→ワクチン→4か月程観察②B の4期間中の ①A死亡5(コロナ死1 ①B死亡16(コロナ死9 ②A死亡9 ②B死亡4 全死因死亡数で全死亡は接種との因果関係が否定されてます(各群八千人程 下記pdf29p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=29 即ち有効性評価期間の①部分でプラセボは3倍以上死亡してます 24%の参加者が基礎疾患持ちです(同45p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=45 11か月×八千人で18人死亡(①A②A②Bの和)はベトナムの年間死亡率の３分の１程です https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN 引用の値は副反応疑い報告で比較はできません https://www.yakuji.co.jp/entry21054.html
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1846089999869268331
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1846114534538518649
- noteId - 1846114534538518649
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1728982978840
- tweetId - 1846089999869268331
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 本治験は A群:ワクチン→3か月程観察①A→プラセボ→4か月程観察②A B群:プラセボ→3か月間観察①B→ワクチン→4か月程観察②B の4期間中の ①A死亡5(コロナ死1 ①B死亡16(コロナ死9 ②A死亡9 ②B死亡4 全死因死亡数で全死亡は接種との因果関係が否定されてます(各群八千人程 下記pdf29p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=29 即ち有効性評価期間の①部分でプラセボは3倍以上死亡してます 24%の参加者が基礎疾患持ちです(同45p https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf#page=45 11か月×八千人で18人死亡(①A②A②Bの和)はベトナムの年間死亡率の３分の１程です https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN 引用の値は副反応疑い報告で比較はできません https://www.yakuji.co.jp/entry21054.html
Note Ratings
| rated at | rated by | |
| 2024-10-15 17:49:46 -0500 | Rating Details | |
| 2024-10-15 16:40:34 -0500 | Rating Details | |
| 2024-10-15 09:38:32 -0500 | Rating Details | |
| 2024-10-15 04:06:41 -0500 | Rating Details | |
| 2024-10-19 02:47:35 -0500 | Rating Details | |
| 2024-10-15 20:58:00 -0500 | Rating Details | |
| 2024-10-15 20:14:51 -0500 | Rating Details | |
| 2024-10-15 17:20:33 -0500 | Rating Details | |
| 2024-10-15 17:19:18 -0500 | Rating Details | |
| 2024-10-15 16:22:48 -0500 | Rating Details | |
| 2024-10-15 10:35:53 -0500 | Rating Details | |
| 2024-10-15 10:01:39 -0500 | Rating Details | |
| 2024-10-15 09:45:40 -0500 | Rating Details | |
| 2024-10-15 08:18:12 -0500 | Rating Details | |
| 2024-10-15 05:43:28 -0500 | Rating Details | |
| 2024-10-15 05:27:31 -0500 | Rating Details | |
| 2024-10-15 05:09:55 -0500 | Rating Details | |
| 2024-10-15 04:18:53 -0500 | Rating Details | |
| 2024-10-17 19:52:03 -0500 | Rating Details | |
| 2024-10-16 23:50:44 -0500 | Rating Details | |
| 2024-10-15 19:14:33 -0500 | Rating Details | |
| 2024-10-15 18:20:41 -0500 | Rating Details | |
| 2024-10-15 17:29:28 -0500 | Rating Details | |
| 2024-10-15 16:39:37 -0500 | Rating Details | |
| 2024-10-15 09:17:29 -0500 | Rating Details | |
| 2024-10-15 09:02:06 -0500 | Rating Details | |
| 2024-10-15 06:03:48 -0500 | Rating Details | |
| 2024-10-15 05:56:02 -0500 | Rating Details | |
| 2024-10-15 05:13:24 -0500 | Rating Details | |
| 2024-10-15 04:14:12 -0500 | Rating Details | |
| 2024-10-15 22:55:50 -0500 | Rating Details | |
| 2024-10-15 19:37:57 -0500 | Rating Details | |
| 2024-10-15 08:37:25 -0500 | Rating Details | |
| 2024-10-15 08:31:35 -0500 | Rating Details | |
| 2024-10-15 06:59:42 -0500 | Rating Details | |
| 2024-10-15 06:38:52 -0500 | Rating Details | |
| 2024-10-15 05:26:56 -0500 | Rating Details | |
| 2024-10-15 05:02:01 -0500 | Rating Details | |
| 2024-10-15 04:58:15 -0500 | Rating Details | |
| 2024-10-15 17:54:33 -0500 | Rating Details | |
| 2024-10-15 16:51:19 -0500 | Rating Details | |
| 2024-10-15 14:56:56 -0500 | Rating Details | |
| 2024-10-15 14:37:34 -0500 | Rating Details | |
| 2024-10-15 13:33:39 -0500 | Rating Details | |
| 2024-10-15 12:24:32 -0500 | Rating Details | |
| 2024-10-15 08:40:08 -0500 | Rating Details | |
| 2024-10-15 07:31:13 -0500 | Rating Details | |
| 2024-10-15 07:24:47 -0500 | Rating Details | |
| 2024-10-15 06:16:03 -0500 | Rating Details | |
| 2024-10-15 04:18:48 -0500 | Rating Details | |
| 2024-10-15 04:11:53 -0500 | Rating Details |